Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major
Study Details
Study Description
Brief Summary
-
Evaluate the therapeutic effects, health benefits, and immunological effect of Al-hijamah in children with beta thalassemia major.
-
Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, in those patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The present study will be carried on 60 children patients with β- thalassemia major attending The Hematology Unit of Paediatric Departments at Tanta University Hospital. Participants will divide into 3 groups:
Group 1: 20 patients receive Al-hijamah.
Group 2: 20 patients receive Al-hijamah plus iron chelation therapy.
Group 3: 20 patients receive iron chelation therapy only
Participants undergo:
- Laboratory investigations:
-
CBC (complete blood count) of peripheral venous blood before Al-hijamah and daily after it.
-
Differences between CBC from venous blood and cupped blood (bloody excretion collected inside suction cups). Cupped blood is collected in heparin coated with and added to suction cups put on the skin surface.
• Serum iron and ferritin before Al-hijamah and after it.
• Serum iron and ferritin in cupped blood vs venous blood.
• Serum lipid profile and glycosylated hemoglobin before Al-hijamah and after it.
-
Total antioxidant capacity and some serum oxidants e.g. malondialdehyde before and after treatment
-
Flow cytometric analysis of number of Natural killer cells, CD4 T helper cells and CD4/CD8 cells (optional) (cluster of differentiation). They were reported to improve markedly after Al-hijamah.
-
Estimating serum LDH, pyruvate (antioxidant) and lactate (metabolite of pyruvate through LDH) in thalassemia patients before and after Al-hijamah
- Assessment of heart function by Echocardiographic study (before and 3 month after
Al-hijamah):
- lines of therapy:
Technical steps of Al-hijamah (Necessary equipments are ready and can do it for all patients if possible):
Al-hijamah (Triple S technique under strict sterilization):
-
Strict sterilization of selected anatomical sites.
-
Suction using sterile plastic disposable sucking cups
-
Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.
-
Suction using sterile plastic disposable sucking cups
-
Strict sterilization of selected anatomical sites.
Study endpoint:
This study will be terminated if safety of the patient were in dangers due to elements related to the new therapeutic agent or if the treatment not proven efficacious.
-
Risks to participants are reasonable in relation to anticipated benefits. Many human studies have proven safety of Al-hijamah.
-
Compensations of controls for transportation or work absence and of patients for any injury, and if so, description of the compensation should be mentioned.
No, compensations.
- The proposal include a clear statement that an informed consent will be obtained from all participants in this research.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group 1: ALhijama 20 patients under went Al-hijamah procedure for iron chelation |
Procedure: Al-hijamah
Strict sterilization of selected anatomical sites.
Suction using sterile plastic disposable sucking cups
Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.
|
| Experimental: Group 2: AL-hijama with deferasirox 20 patients receive deferasirox and Al-hijamah. |
Procedure: Al-hijamah
Strict sterilization of selected anatomical sites.
Suction using sterile plastic disposable sucking cups
Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.
Drug: Deferasirox
20-40 mg/kg/day orally
|
| Active Comparator: Group 3:deferasirox 20 patients already receiving deferasirox |
Drug: Deferasirox
20-40 mg/kg/day orally
|
Outcome Measures
Primary Outcome Measures
- CD(cluster of differentiation)4 and CD8 count [3month]
count and percentage
Secondary Outcome Measures
- serum levels of cholesterol and triglyceride [3month]
level of cholesterol and triglyceride (mg per dl)
- alanine amino transferase , aspartate amino transferase [3month]
measured as unit per litre
- serum ferritin [3 months]
measured as ng per dl
- malodialdehyde ant total antioxidant capacity [3 months]
measuedas mmol per litre
Eligibility Criteria
Criteria
Inclusion Criteria:
- Children suffering from beta thalassemia major, with age range from 4-18 years.
Exclusion Criteria:
-
Children with Congenital heart disease
-
Children with Rheumatic heart disease
-
Presence of heart failure
-
Children with Coronary arterial disease
-
Children with Cardiomyopathy
-
Children with hypotension
-
Children with inflammatory skin diseases e.g. acute burns
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Faculty of Medicine- Tanta University | Tanta | Gharbia | Egypt | 0000 |
| 2 | Faculty of Medicine- Tanta University | Tanta | Gharbia | Egypt | 0000 |
Sponsors and Collaborators
- Tanta University
Investigators
- Study Director: Mohamed ELshanshory, prof, ethical committee
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2814/10/14